Tango Therapeutics, Inc.

NasdaqGM:TNGX Stock Report

Market Cap: US$747.9m

Tango Therapeutics Future Growth

Future criteria checks 2/6

Tango Therapeutics's earnings are forecast to decline at 3.9% per annum while its annual revenue is expected to grow at 27.5% per year. EPS is expected to decline by 0.3% per annum.

Key information

-3.9%

Earnings growth rate

-0.3%

EPS growth rate

Biotechs earnings growth28.8%
Revenue growth rate27.5%
Future return on equityn/a
Analyst coverage

Good

Last updated10 Sep 2024

Recent future growth updates

Recent updates

Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data

Sep 10

What Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 29% Share Price Gain Is Not Telling You

Sep 01
What Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 29% Share Price Gain Is Not Telling You

Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 27%

Jun 29
Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 27%

Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why

May 30
Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why

Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%

Mar 19
Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%

Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans

Mar 06
Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk

Jan 08
Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk

Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%

Nov 09
Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%

New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)

Aug 12
New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)

Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?

May 10
Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?

Tango Therapeutics started at buy at Wainwright on synthetically lethal targets for cancer

Oct 20

Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth

Oct 05
Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth

Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Aug 13
Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Tango Therapeutics GAAP EPS of -$0.28 beats by $0.03, revenue of $5.78M beats by $0.12M

Aug 10

We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn

May 28
We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn

We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow

Jan 06
We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow

Earnings and Revenue Growth Forecasts

NasdaqGM:TNGX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202633-185-170-1778
12/31/202532-169-164-1669
12/31/202442-140-160-1319
6/30/202443-116-121-120N/A
3/31/202437-112-122-121N/A
12/31/202337-102-120-118N/A
9/30/202338-100-121-119N/A
6/30/202334-107-113-107N/A
3/31/202325-111-121-114N/A
12/31/202225-108-117-109N/A
9/30/202224-101-105-98N/A
6/30/202224-92-104-100N/A
3/31/202236-71-79-76N/A
12/31/202137-58-61-60N/A
9/30/202140-45-62-61N/A
6/30/202122-527172N/A
3/31/20219-566769N/A
12/31/20208-526970N/A
12/31/201925-14-27-25N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TNGX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TNGX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TNGX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TNGX's revenue (27.5% per year) is forecast to grow faster than the US market (8.7% per year).

High Growth Revenue: TNGX's revenue (27.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TNGX's Return on Equity is forecast to be high in 3 years time


Discover growth companies